Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$11.39 - $70.40
Next Earnings Date
Apr 29 2025
Next Earnings Date
Apr 29 2025
Latest price
Market Cap | $5.38B |
EV | $5.21B |
Shares Outstanding | 88.11M |
Beta | 0.16 |
Analyst Rating | BUY |
Analyst Target Price | $80.89 |
P/E 2025E | - |
P/Revenue 2025E | 16.63x |
Revenue | 1.10% |
EPS | -29.50% |
Operating Cash Flow | -53.10% |
Free Cash Flow | - |
Revenue | 164.40% |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin 2025E | 95.00% |
Net Profit Margin 2025E | 3.59% |
ROE 2025E | - |
ROCE 2024 | -76.42% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Verona Pharma plc
VRNA
Sector
Healthcare
Industry
Biotechnology
CEO
Zaccardelli, David
Employees
209
Website
www.veronapharma.comIPO Date
2017-04-28
Headquarters
3 More London Riverside, London, Greater London, SE1 2RE, United Kingdom
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved